RHYTHM PHARMACEUTICALS WKN: A2H5A0 ISIN: US76243J1051 Kürzel: RYTM Forum: Aktien Thema: Hauptdiskussion

Bald 100% in einem Monat 👍🏻

Ziemlich wenig los hier. Richtig stabile Monstsperformance. Gewinne sichern.

https://www.benzinga.com/pressreleases/22/02/g25658919/rhythm-pharmaceuticals-announces-positive-interim-data-from-long-term-extension-study-of-setmelano

Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) said Keith Gottesdiener will step down as CEO, president and board member after the completion of its NDA submission for setmelanotide, a MC4R agonist, for the treatment of pro-opiomelanocortin and leptin receptor deficiency obesities. The company said it expects to complete the rolling submission of the NDA by the first quarter of 2020. The company also reiterated its previous guidance on major milestones, including a Phase 3 top-*** data readout for setmelanotide in Bardet-Biedl and Alström syndromes in the fourth quarter of 2020 or early in the first quarter of 2021. Rhythm also said it is well-capitalized, with sufficient resources to fund its operations through at least the end of 2021